NBTX
Closed
Nanobiotix
4.5662
-0.1638 (-3.46%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 4.73
Day's Range: 4.5662 - 4.8
Send
sign up or login to leave a comment!
When Written:
3.649
Nanobiotix is a French clinical-stage nanomedicine company that focuses on developing innovative cancer therapies. The company's lead product candidate, NBTXR3, is a nanoparticle-based radio-enhancer that is designed to increase the effectiveness of radiation therapy in cancer patients. NBTXR3 is currently being evaluated in clinical trials for the treatment of various types of cancer, including head and neck cancer, soft tissue sarcoma, and rectal cancer.
Nanobiotix's technology platform is based on the use of nanoparticles that can be designed to selectively target cancer cells and deliver therapeutic agents directly to the tumor site. The company's proprietary nanoparticle technology is designed to enhance the therapeutic efficacy of existing cancer treatments, such as radiation therapy and chemotherapy, while minimizing side effects.
Nanobiotix was founded in 2003 and is headquartered in Paris, France. The company is publicly traded on the Euronext Paris exchange under the ticker symbol NANO.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Nanobiotix's technology platform is based on the use of nanoparticles that can be designed to selectively target cancer cells and deliver therapeutic agents directly to the tumor site. The company's proprietary nanoparticle technology is designed to enhance the therapeutic efficacy of existing cancer treatments, such as radiation therapy and chemotherapy, while minimizing side effects.
Nanobiotix was founded in 2003 and is headquartered in Paris, France. The company is publicly traded on the Euronext Paris exchange under the ticker symbol NANO.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








